JP2020511468A - Ｍｋ２阻害剤の重水素化アナログおよびその使用 - Google Patents

Ｍｋ２阻害剤の重水素化アナログおよびその使用 Download PDF

Info

Publication number
JP2020511468A
JP2020511468A JP2019550653A JP2019550653A JP2020511468A JP 2020511468 A JP2020511468 A JP 2020511468A JP 2019550653 A JP2019550653 A JP 2019550653A JP 2019550653 A JP2019550653 A JP 2019550653A JP 2020511468 A JP2020511468 A JP 2020511468A
Authority
JP
Japan
Prior art keywords
compound
deuterium
certain embodiments
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511468A5 (https=
Inventor
ジョン・マロナ
セカル・エス・スラパネニ
Original Assignee
セルジーン シーエーアール エルエルシー
セルジーン シーエーアール エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン シーエーアール エルエルシー, セルジーン シーエーアール エルエルシー filed Critical セルジーン シーエーアール エルエルシー
Publication of JP2020511468A publication Critical patent/JP2020511468A/ja
Publication of JP2020511468A5 publication Critical patent/JP2020511468A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2019550653A 2017-03-16 2018-03-15 Ｍｋ２阻害剤の重水素化アナログおよびその使用 Pending JP2020511468A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472022P 2017-03-16 2017-03-16
US62/472,022 2017-03-16
PCT/US2018/022545 WO2018170201A1 (en) 2017-03-16 2018-03-15 Deuterated analogs of mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2020511468A true JP2020511468A (ja) 2020-04-16
JP2020511468A5 JP2020511468A5 (https=) 2021-04-22

Family

ID=63523341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550653A Pending JP2020511468A (ja) 2017-03-16 2018-03-15 Ｍｋ２阻害剤の重水素化アナログおよびその使用

Country Status (4)

Country Link
US (1) US11230551B2 (https=)
EP (1) EP3596085A4 (https=)
JP (1) JP2020511468A (https=)
WO (1) WO2018170201A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512315A (ja) * 2017-03-16 2020-04-23 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN115925718A (zh) * 2022-12-27 2023-04-07 瑞石生物医药有限公司 一种四环内酰胺衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
JP2020512315A (ja) * 2017-03-16 2020-04-23 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
HK1210696A1 (en) * 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
US9457707B2 (en) * 2014-09-15 2016-10-04 Nissan North America, Inc. Vehicle auxiliary lamp unit
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
JP2020512315A (ja) * 2017-03-16 2020-04-23 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOSTER, AB: "Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design", ADVANCES IN DRUG RESEARCH, vol. 14, JPN5014006660, 1985, pages 1 - 40, XP009086953, ISSN: 0004721940 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512315A (ja) * 2017-03-16 2020-04-23 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物

Also Published As

Publication number Publication date
EP3596085A1 (en) 2020-01-22
US20210122762A1 (en) 2021-04-29
WO2018170201A1 (en) 2018-09-20
EP3596085A4 (en) 2020-11-25
US11230551B2 (en) 2022-01-25

Similar Documents

Publication Publication Date Title
JP7200120B2 (ja) Ｍｋ２阻害剤として有用なヘテロアリール化合物
JP2020511468A (ja) Ｍｋ２阻害剤の重水素化アナログおよびその使用
CN108602776B (zh) 用作irak抑制剂的杂芳基化合物及其用途
JP6802251B2 (ja) 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
JP5406725B2 (ja) タンパク質キナーゼ阻害剤として有用な化合物
KR101432316B1 (ko) 증식성 장애의 치료를 위한 단백질 키나제 ｐｌｋ1 억제제로서의 4,5-디히드로-［1,2,4］트리아졸로［4,3-ｆ］프테리딘
ES2672530T3 (es) Amidas heterocíclicas como inhibidores de cinasas
KR101749953B1 (ko) α7 양성 알로스테릭 조절제로서의 모르폴리노티아졸
AU2023207390A1 (en) Six-membered cyclothiazole compound and use thereof
AU2012266941B2 (en) Substituted pyridopyrazines as novel Syk inhibitors
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
AU2021269397B2 (en) Compounds and compositions for the treatment of cancer
SA517380651B1 (ar) مثبطات ديميثيلاز-1 خاص بلايسين
EA027563B1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
JP2008524191A (ja) Ｃｄｋ阻害剤としての４−（４−（イミダゾール−４−イル）ピリミジン−２−イルアミノ）ベンズアミド
EP3883925A1 (en) Cyclic ureas
CN109956957A (zh) 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
KR20200007000A (ko) 아폽토시스 신호 조절 키나아제 １ 억제제 및 이의 사용 방법
CN108884066A (zh) 作为蛋白激酶抑制剂的新的2，3，5-取代的噻吩化合物
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
CN117279636A (zh) 用于调节强直性肌营养不良1型的方法和化合物
EP3600451B1 (en) Agents for differentiating stem cells and treating cancer
KR20250012101A (ko) Parg의 억제제
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220621